11β-Hydroxysteroid dehydrogenase 1 inhibition attenuates collagen-induced arthritis

Area of Science:

• Biochemistry
• Immunology
• Pharmacology

Background:

• 11β-Hydroxysteroid dehydrogenase 1 (11β-HSD1) is implicated in inflammatory processes.
• The specific role of 11β-HSD1 in rheumatoid arthritis (RA) pathogenesis is not well understood.

Purpose of the Study:

• To investigate the therapeutic potential of the selective 11β-HSD1 inhibitor BVT-2733 in collagen-induced arthritis (CIA).
• To elucidate the underlying molecular mechanisms of BVT-2733's action in arthritis.

Main Methods:

• CIA mice were administered BVT-2733 (100 mg/kg, orally) or vehicle twice daily for two weeks.
• Arthritis severity, joint histology, pro-inflammatory cytokine levels, anti-type II collagen antibody (anti-CII) titers, and NF-κB/NLRP1 inflammasome activation were assessed.

Main Results:

• BVT-2733 treatment significantly reduced arthritis severity and joint destruction in CIA mice.
• The inhibitor decreased serum levels of TNF-α, IL-1β, IL-6, and IL-17, as well as anti-CII antibodies.
• BVT-2733 inhibited NF-κB activation and NLRP1 inflammasome assembly in joint tissues and human RA synovial cells.

Conclusions:

• BVT-2733 demonstrates significant anti-inflammatory and protective effects in a preclinical model of rheumatoid arthritis.
• These beneficial effects are mediated, at least in part, by the suppression of NF-κB and NLRP1 inflammasome signaling pathways.
• Targeting 11β-HSD1 with inhibitors like BVT-2733 represents a potential novel therapeutic strategy for managing rheumatoid arthritis.